References
- Lichtman MA. A historical perspective on the development of the cytarabine (7days) and daunorubicin (3days) treatment regimen for acute myelogenous leukemia: 2013 the 40th anniversary of 7+3. Blood Cells Mol Dis 2013; 50:119 - 30; http://dx.doi.org/10.1016/j.bcmd.2012.10.005; PMID: 23154039
- Madani TA. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection 2000; 28:367 - 73; http://dx.doi.org/10.1007/s150100070007; PMID: 11139156
- Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65:293 - 5; http://dx.doi.org/10.1093/jac/dkp444; PMID: 20016020
- Garcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob Agents Chemother 2008; 52:4181 - 3; http://dx.doi.org/10.1128/AAC.00802-08; PMID: 18794386
- Lewis RE, Viale P, Kontoyiannis DP. The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida.. Virulence 2012; 3:368 - 76; http://dx.doi.org/10.4161/viru.20746; PMID: 22722245
- Ahearn DG, McGlohn MS. In vitro susceptibilities of sucrose-negative Candida tropicalis, Candida lusitaniae, and Candida norvegensis to amphotericin B, 5-fluorocytosine, miconazole, and ketoconazole. J Clin Microbiol 1984; 19:412 - 6; PMID: 6325491
- Linares CEB, Griebeler D, Cargnelutti D, Alves SH, Morsch VM, Schetinger MRC. Catalase activity in Candida albicans exposed to antineoplastic drugs. J Med Microbiol 2006; 55:259 - 62; http://dx.doi.org/10.1099/jmm.0.46263-0; PMID: 16476788
- Kofla G, Turner V, Schulz B, Storch U, Froelich D, Rognon B, et al. Doxorubicin induces drug efflux pumps in Candida albicans. Med Mycol 2011; 49:132 - 42; http://dx.doi.org/10.3109/13693786.2010.512022; PMID: 20818920
- Rosen DB, Cordeiro JA, Cohen A, Lacayo N, Hogge D, Hawtin RE, et al. Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML. Leuk Res 2012; 36:900 - 4; http://dx.doi.org/10.1016/j.leukres.2012.02.022; PMID: 22521550
- Clinical Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Wayne, PA: Clinical Laboratory Standards Institute, 2008.
- Ben-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, et al. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. J Infect Dis 2011; 204:626 - 35; http://dx.doi.org/10.1093/infdis/jir351; PMID: 21791665
- Chamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, et al. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. J Infect Dis 2006; 193:1014 - 22; http://dx.doi.org/10.1086/500950; PMID: 16518764